Skip to main content

Table 12 Selected studies for ALL therapy from 2020 ASH annual meeting

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Abstract # Authors (reference) Study agents Phase NCT No
465 Short et al. [148] Ponatinib
Venetoclax dexamethasone
I/II 03576547
3347 Ghobadi et al. [151] AlloHSCT versus chemotherapy Multicenter
Retrospective
 
1014 Short et al. [155] MiniHCVD
Inotuzumab ozogamicin
Blinatumomab
II  
163 Jain et al. [158] UCART22 I 04150497
499 Hu et al. [159] CTA101 I 04154709
  1. ALL, acute lymphoblastic leukemia; AlloHSCT, allogeneic hematopoietic stem cell transplantation; HCVD, fractionated cyclophosphamide, vincristine, dexamethasone